secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001104659-23-029687
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 3.02, 3.03, 4.01, 5.01, 5.02, 5.03, 5.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics completes reverse merger with Sesen Bio; begins trading as CARM
--------------------------------------------------------------------------------

- Merger closed March 7, 2023; Sesen Bio renamed Carisma Therapeutics; ticker changes from SESN to CARM on Nasdaq.
- Pre-closing financing of ~$30.6M from Carisma investors purchased 1,964,101 shares; $35M convertible note converted.
- Post-merger ~40.25M shares outstanding; exchange ratio allocated ownership between legacy Sesen and Carisma holders.
- CVRs issued to pre-merger Sesen stockholders for potential payments from Roche milestone or asset sales.
- Auditor changed: Ernst & Young dismissed; KPMG engaged as new independent auditor for FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/0001104659-23-029687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer